Erratum: The AST infectious diseases community of practice, aspergillosis in solid organ transplantation (American Journal of Transplantation (2013) 13 (228-241) DOI: 10.1111/ajt.12115);Aspergillosis in solid organ transplantation

American Journal of Transplantation

Volumn 13, Issue SUPPL.4, 2013, Pages 228-241

  Singh, N M ^a   Husain, S ^b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Antifungal; aspergillosis; invasive fungal infections; opportunistic infection; pulmonary infection

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; CASPOFUNGIN; CYCLOSPORIN A; ECHINOCANDIN; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; RAPAMYCIN; TACROLIMUS; VORICONAZOLE;

ARTICLE; GRAFT RECIPIENT; HEART GRAFT; HUMAN; INVASIVE ASPERGILLOSIS; KIDNEY GRAFT; LIVER GRAFT; LUNG TRANSPLANTATION; MORTALITY; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; RISK FACTOR; SOLID ORGAN TRANSPLANTATION;

EID: 84874891182     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12270     Document Type: Erratum

References (139)

1. Morgan J, Wannemuehler KA, Marr KA, et al. Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: Interim results of a prospective multicenter surveillance program. Med Mycol 2005; 43(Suppl 1): S49-S58.
2. Singh N, Arnow PM, Bonham A, et al. Invasive aspergillosis in liver transplant recipients in the 1990s. Transplantation 1997; 64: 716-720.
3. Singh N, Avery RK, Munoz P, et al. Trends in risk profiles for and mortality associated with invasive aspergillosis among liver transplant recipients. Clin Infect Dis 2003; 36: 46-52.
4. Gavalda J, Len O, San JR, et al. Risk factors for invasive aspergillosis in solid-organ transplant recipients: A case-control study. Clin Infect Dis 2005; 41: 52-59.
5. Steinbach WJ, Marr KA, Anaissie EJ, et al. Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH Alliance registry. J Infect 2012; 65: 453-464.
6. Paterson DL, Singh N,. Invasive aspergillosis in transplant recipients. Medicine (Baltimore) 1999; 78: 123-138.
7. Brown RS, Jr., Lake JR, Katzman BA, et al. Incidence and significance of Aspergillus cultures following liver and kidney transplantation. Transplantation 1996; 61: 666-669.
8. Briegel J, Forst H, Spill B, et al. Risk factors for systemic fungal infections in liver transplant recipients. Eur J Clin Microbiol Infect Dis 1995; 14: 375-382.
9. Kusne S, Torre-Cisneros J, Manez R, et al. Factors associated with invasive lung aspergillosis and the significance of positive Aspergillus culture after liver transplantation. J Infect Dis 1992; 166: 1379-1383.
10. Singh N, Paterson DL,. Aspergillus infections in transplant recipients. Clin Microbiol Rev 2005; 18: 44-69.
11. Fortun J, Martin-Davila P, Moreno S, et al. Risk factors for invasive aspergillosis in liver transplant recipients. Liver Transpl 2002; 8: 1065-1070.
12. Singh N, Paterson DL, Gayowski T, Wagener MM, Marino IR,. Preemptive prophylaxis with a lipid preparation of amphotericin B for invasive fungal infections in liver transplant recipients requiring renal replacement therapy. Transplantation 2001; 71: 910-913.
13. Singh N, Limaye AP, Forrest G, et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: A prospective, multicenter, observational study. Transplantation 2006; 81: 320-326.
14. Osawa M, Ito Y, Hirai T, et al. Risk factors for invasive aspergillosis in living donor liver transplant recipients. Liver Transpl 2007; 13: 566-570.
15. George MJ, Snydman DR, Werner BG, et al. The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, MedImmune, Inc. Gaithersburg, Maryland. Am J Med 1997; 103: 106-113.
16. Collins LA, Samore MH, Roberts MS, et al. Risk factors for invasive fungal infections complicating orthotopic liver transplantation. J Infect Dis 1994; 170: 644-652.
17. Selby R, Ramirez CB, Singh R, et al. Brain abscess in solid organ transplant recipients receiving cyclosporine-based immunosuppression. Arch Surg 1997; 132: 304-310.
18. Denning DW., Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 1996; 23: 608-615.
19. Fortun J, Martin-Davila P, Moreno S, et al. Prevention of invasive fungal infections in liver transplant recipients: The role of prophylaxis with lipid formulations of amphotericin B in high-risk patients. J Antimicrob Chemother 2003; 52: 813-819.
20. Altiparmak MR, Apaydin S, Trablus S, et al. Systemic fungal infections after renal transplantation. Scand J Infect Dis 2002; 34: 284-288.
21. Cofan F, Ricart MJ, Oppenheimer F, et al. Study of kidney rejection following simultaneous kidney-pancreas transplantation. Nephron 1996; 74: 58-63.
22. Weiland D, Ferguson RM, Peterson PK, Snover DC, Simmons RL, Najarian JS,. Aspergillosis in 25 renal transplant patients. Epidemiology, clinical presentation, diagnosis, and management. Ann Surg 1983; 198: 622-629.
23. Gustafson TL, Schaffner W, Lavely GB, Stratton CW, Johnson HK, Hutcheson RH, Jr., Invasive aspergillosis in renal transplant recipients: Correlation with corticosteroid therapy. J Infect Dis 1983; 148: 230-238.
24. Peterson PK, Ferguson R, Fryd DS, Balfour HH, Jr., Rynasiewicz J, Simmons RL,. Infectious diseases in hospitalized renal transplant recipients: A prospective study of a complex and evolving problem. Medicine (Baltimore) 1982; 61: 360-372.
25. Gallis HA, Berman RA, Cate TR, Hamilton JD, Gunnells JC, Stickel DL,. Fungal infection following renal transplantation. Arch Intern Med 1975; 135: 1163-1172.
26. Panackal AA, Dahlman A, Keil KT, et al. Outbreak of invasive aspergillosis among renal transplant recipients. Transplantation 2003; 75: 1050-1053.
27. Husain S, Paterson DL, Studer S, et al. Voriconazole prophylaxis in lung transplant recipients. Am J Transplant 2006; 6: 3008-3016.
28. Pappas PG, Alexander BD, Andes DR, et al. Invasive fungal infections among organ transplant recipients: Results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis 2010; 50: 1101-1111.
29. Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: Overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 2010; 50: 1091-1100.
30. Neofytos D, Fishman JA, Horn D, et al. Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients. Transpl Infect Dis 2010.
31. Chan KM., Approach towards infectious pulmonary complications in lung tramnsplant recipients. In:, Singh N, Aguado JM, eds. Infectious complications in transplant aptients. 1st Ed. Kluwer Academic Publishers: Norwell, MA; 2001, pp. 149-175.
32. Higgins R, McNeil K, Dennis C, et al. Airway stenoses after lung transplantation: Management with expanding metal stents. J Heart Lung Transplant 1994; 13: 774-778.
33. Westney GE, Kesten S, De Hoyos A, Chapparro C, Winton T, Maurer JR,. Aspergillus infection in single and double lung transplant recipients. Transplantation 1996; 61: 915-919.
34. Goldfarb NS, Avery RK, Goormastic M, et al. Hypogammaglobulinemia in lung transplant recipients. Transplantation 2001; 71: 242-246.
35. Husni RN, Gordon SM, Longworth DL, et al. Cytomegalovirus infection is a risk factor for invasive aspergillosis in lung transplant recipients. Clin Infect Dis 1998; 26: 753-755.
36. Cahill BC, Hibbs JR, Savik K, et al. Aspergillus airway colonization and invasive disease after lung transplantation. Chest 1997; 112: 1160-1164.
37. Nunley DR, Ohori P, Grgurich WF, et al. Pulmonary aspergillosis in cystic fibrosis lung transplant recipients. Chest 1998; 114: 1321-1329.
38. Helmi M, Love RB, Welter D, Cornwell RD, Meyer KC,. Aspergillus infection in lung transplant recipients with cystic fibrosis: Risk factors and outcomes comparison to other types of transplant recipients. Chest 2003; 123: 800-808.
39. Valentine VG, Bonvillain RW, Gupta MR, et al. Infections in lung allograft recipients: Ganciclovir era. J Heart Lung Transplant 2008; 27: 528-535.
40. Munoz P, Singh N, Bouza E,. Treatment of solid organ transplant patients with invasive fungal infections: Should a combination of antifungal drugs be used? Curr Opin Infect Dis 2006; 19: 365-370.
41. Berenguer J, Munoz P, Parras F, Fernandez-Baca V, Hernandez-Sampelayo T, Bouza E,. Treatment of deep mycoses with liposomal amphotericin B. Eur J Clin Microbiol Infect Dis 1994; 13: 504-507.
42. Munoz P, Rodriguez C, Bouza E, et al. Risk factors of invasive aspergillosis after heart transplantation: Protective role of oral itraconazole prophylaxis. Am J Transplant 2004; 4: 636-643.
43. Munoz P, Alcala L, Sanchez CM, et al. The isolation of Aspergillus fumigatus from respiratory tract specimens in heart transplant recipients is highly predictive of invasive aspergillosis. Transplantation 2003; 75: 326-329.
44. De PB, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813-1821.
45. Husain S, Mooney ML, Danziger-Isakov L, et al. A 2010 working formulation for the standardization of definitions of infections in cardiothoracic transplant recipients. J Heart Lung Transplant 2011; 30: 361-374.
46. Mehrad B, Paciocco G, Martinez FJ, Ojo TC, Iannettoni MD, Lynch JP, III,. Spectrum of Aspergillus infection in lung transplant recipients: Case series and review of the literature. Chest 2001; 119: 169-175.
47. Fortun J, Martin-Davila P, Alvarez ME, et al. Aspergillus antigenemia sandwich-enzyme immunoassay test as a serodiagnostic method for invasive aspergillosis in liver transplant recipients. Transplantation 2001; 71: 145-149.
48. Kwak EJ, Husain S, Obman A, et al. Efficacy of galactomannan antigen in the Platelia Aspergillus enzyme immunoassay for diagnosis of invasive aspergillosis in liver transplant recipients. J Clin Microbiol 2004; 42: 435-438.
49. Husain S, Kwak EJ, Obman A, et al. Prospective assessment of Platelia Aspergillus galactomannan antigen for the diagnosis of invasive aspergillosis in lung transplant recipients. Am J Transplant 2004; 4: 796-802.
50. Pfeiffer CD, Fine JP, Safdar N,. Diagnosis of invasive aspergillosis using a galactomannan assay: A meta-analysis. Clin Infect Dis 2006; 42: 1417-1727.
51. Husain S, Paterson DL, Studer SM, et al. Aspergillus galactomannan antigen in the bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in lung transplant recipients. Transplantation 2007; 83: 1330-1336.
52. Clancy CJ, Jaber RA, Leather HL, et al. Bronchoalveolar lavage galactomannan in diagnosis of invasive pulmonary aspergillosis among solid-organ transplant recipients. J Clin Microbiol 2007; 45: 1759-1765.
53. Husain S, Clancy CJ, Nguyen MH, et al. Performance characteristics of the platelia Aspergillus enzyme immunoassay for detection of Aspergillus galactomannan antigen in bronchoalveolar lavage fluid. Clin Vaccine Immunol 2008; 15: 1760-1763.
54. Singh N, Husain H., Aspergillus infections after lung transplantation: Clinical differences in type of transplant and implications for management. J Heart Lung Transplant 2003; 22: 258-266.
55. Kawagishi N, Satoh K, Enomoto Y, et al. Risk factors and impact of beta-D glucan on invasive fungal infection for the living donor liver transplant recipients. Tohoku J Exp Med 2006; 209: 207-215.
56. Alexander BD, Smith PB, Davis RD, Perfect JR, Reller LB., The 1,3-β-D-glucan test as an aid to early diagnosis of invasive fungal infections following lung transplantation. J Clin Microbiol 2010; 48: 4083-4088.
57. Badiee P, Kordbacheh P, Alborzi A, Malekhoseini SA,. Invasive fungal infection in renal transplant recipients demonstrated by panfungal polymerase chain reaction. Exp Clin Transplant 2007; 5: 624-629.
58. Luong ML, Clancy CJ, Vadnerkar A, et al. Comparison of an Aspergillus real-time polymerase chain reaction assay with galactomannan testing of bronchoalvelolar lavage fluid for the diagnosis of invasive pulmonary aspergillosis in lung transplant recipients. Clin Infect Dis 2011; 52: 1218-1226.
59. Park YS, Seo JB, Lee YK, et al. Radiological and clinical findings of pulmonary aspergillosis following solid organ transplant. Clin Radiol 2008; 63: 673-680.
60. Linden PK, Coley K, Fontes P, Fung JJ, Kusne S., Invasive aspergillosis in liver transplant recipients: Outcome comparison of therapy with amphotericin B lipid complex and a historical cohort treated with conventional amphotericin B. Clin Infect Dis 2003; 37: 17-25.
61. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-415.
62. Fortun J, Martin-Davila P, Sanchez MA, et al. Voriconazole in the treatment of invasive mold infections in transplant recipients. Eur J Clin Microbiol Infect Dis 2003; 22: 408-413.
63. Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002; 34: 563-571.
64. Veroux M, Corona D, Gagliano M, et al. Voriconazole in the treatment of invasive aspergillosis in kidney transplant recipients. Transplant Proc 2007; 39: 1838-1840.
65. Schwartz S, Ruhnke M, Ribaud P, et al. Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood 2005; 106: 2641-2645.
66. Weclawiak H, Garrouste C, Kamar N, et al. Aspergillus fumigatus-related spondylodiscitis in a heart transplant patient successfully treated with voriconazole. Transplant Proc 2007; 39: 2627-2628.
67. Wieland T, Liebold A, Jagiello M, Retzl G, Birnbaum DE,. Superiority of voriconazole over amphotericin B in the treatment of invasive aspergillosis after heart transplantation. J Heart Lung Transplant 2005; 24: 102-104.
68. Baddley JW, Andes DR, Marr KA, et al. Antifungal therapy and length of hospitalization in transplant patients with invasive aspergillosis. Med Mycol 2012.
69. Kramer M, Kramer MR, Blau H, Bishara J, xer-Siegel R, Weinberger D,. Intravitreal voriconazole for the treatment of endogenous Aspergillus endophthalmitis. Ophthalmology 2006; 113: 1184-1186.
70. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: Clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 327-360.
71. Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: An externally controlled trial. Clin Infect Dis 2007; 44: 2-12.
72. Carby MR, Hodson ME, Banner NR,. Refractory pulmonary aspergillosis treated with caspofungin after heart-lung transplantation. Transpl Int 2004; 17: 545-548.
73. Aguado JM, Varo E, Usetti P, et al. Safety of anidulafungin in solid organ transplant recipients. Liver Transpl 2012; 18: 680-685.
74. Wadi J, Al-kawasmeh SI, Kamel MT, AlJayyousi BB,. Disseminated invasive aspergillosis successfully treated with micafungin in a renal transplant recipient. Saudi J Kidney Dis Transpl 2010; 21: 914-918.
75. Marr KA, Schlamm H, Rottinghaus S, et al. A randomized, double-blind study of combination antifungal therapy with voriconazole and anidulafungin versus voriconazole monotherapy for primary treatment of invasive aspergillosis. In Proceedings of the 22nd European Congress of Clinical Microbiology and Infectious Diseases, London, April 2012. 4-1-2012.
76. Anonymous. Voriconazole. Med Lett Drug Ther 2002; 44: 63-65.
77. Singh N, Wagener MM, Cacciarelli TV, Levitsky J,. Antifungal management practices in liver transplant recipients. Am J Transplant 2008; 8: 426-431.
78. Rea F, Marulli G, Loy M, et al. Salvage right pneumonectomy in a patient with bronchial-pulmonary artery fistula after bilateral sequential lung transplantation. J Heart Lung Transplant 2006; 25: 1383-1386.
79. Scherer M, Fieguth HG, Aybek T, Ujvari Z, Moritz A, Wimmer-Greinecker G,. Disseminated Aspergillus fumigatus infection with consecutive mitral valve endocarditis in a lung transplant recipient. J Heart Lung Transplant 2005; 24: 2297-2300.
80. Hummel M, Schuler S, Weber U, et al. Aspergillosis with Aspergillus osteomyelitis and diskitis after heart transplantation: Surgical and medical management. J Heart Lung Transplant 1993; 12: 599-603.
81. Loria KM, Salinger MH, Frohlich TG, Gendelman MD, Cook FV, Arentzen CE,. Primary cutaneous aspergillosis in a heart transplant recipient treated with surgical excision and oral itraconazole. J Heart Lung Transplant 1992; 11 (Pt 1): 156-159.
82. Lodge BA, Ashley ED, Steele MP, Perfect JR,. Aspergillus fumigatus empyema, arthritis, and calcaneal osteomyelitis in a lung transplant patient successfully treated with posaconazole. J Clin Microbiol 2004; 42: 1376-1378.
83. Shlobin OA, Dropulic LK, Orens JB, et al. Mediastinal mass due to Aspergillus fumigatus after lung transplantation: A case report. J Heart Lung Transplant 2005; 24: 1991-1994.
84. Sandur S, Gordon SM, Mehta AC, Maurer JR,. Native lung pneumonectomy for invasive pulmonary aspergillosis following lung transplantation: A case report. J Heart Lung Transplant 1999; 18: 810-813.
85. Saad AH, DePestel DD, Carver PL,. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy 2006; 26: 1730-1744.
86. Leather H, Boyette RM, Tian L, Wingard JR,. Pharmacokinetic evaluation of the drug interaction between intravenous itraconazole and intravenous tacrolimus or intravenous cyclosporin A in allogeneic hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant 2006; 12: 325-334.
87. Wimberley SL, Haug MT, III, Shermock KM, et al. Enhanced cyclosporine-itraconazole interaction with cola in lung transplant recipients. Clin Transplant 2001; 15: 116-122.
88. Marty FM, Bryar J, Browne SK, et al. Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: A cohort analysis. Blood 2007; 110: 490-500.
89. Mathis AS, Shah NK, Friedman GS,. Combined use of sirolimus and voriconazole in renal transplantation: A report of two cases. Transplant Proc 2004; 36: 2708-2709.
90. Sansone-Parsons A, Krishna G, Martinho M, Kantesaria B, Gelone S, Mant TG,. Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus. Pharmacotherapy 2007; 27: 825-834.
91. Sable CA, Nguyen BY, Chodakewitz JA, DiNubile MJ,. Safety and tolerability of caspofungin acetate in the treatment of fungal infections. Transpl Infect Dis 2002; 4: 25-30.
92. Saner F, Gensicke J, Rath P, et al. Safety profile of concomitant use of caspofungin and cyclosporine or tacrolimus in liver transplant patients. Infection 2006; 34: 328-332.
93. Sanz-Rodriguez C, Lopez-Duarte M, Jurado M, et al. Safety of the concomitant use of caspofungin and cyclosporin A in patients with invasive fungal infections. Bone Marrow Transplant 2004; 34: 13-20.
94. Anttila VJ, Piilonen A, Valtonen M,. Co-administration of caspofungin and cyclosporine to a kidney transplant patient with pulmonary Aspergillus infection. Scand J Infect Dis 2003; 35: 893-894.
95. Vazquez JA, Sobel JD,. Anidulafungin: A novel echinocandin. Clin Infect Dis 2006; 43: 215-222.
96. Dowell JA, Stogniew M, Krause D, Henkel T, Weston IE,. Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine. J Clin Pharmacol 2005; 45: 227-233.
97. Joseph JM, Jain R, Danziger LH,. Micafungin: A new echinocandin antifungal. Pharmacotherapy 2007; 27: 53-67.
98. Hebert MF, Townsend RW, Austin S, et al. Concomitant cyclosporine and micafungin pharmacokinetics in healthy volunteers. J Clin Pharmacol 2005; 45: 954-960.
99. Chandrasekar PH, Sobel JD,. Micafungin: A new echinocandin. Clin Infect Dis 2006; 42: 1171-1178.
100. Gil-Lamaignere C, Simitsopoulou M, Roilides E, Maloukou A, Winn RM, Walsh TJ,. Interferon-gamma and granulocyte-macrophage colony-stimulating factor augment the activity of polymorphonuclear leukocytes against medically important zygomycetes. J Infect Dis 2005; 191: 1180-1187.
101. Vora S, Chauhan S, Brummer E, Stevens DA,. Activity of voriconazole combined with neutrophils or monocytes against Aspergillus fumigatus: Effects of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. Antimicrob Agents Chemother 1998; 42: 2299-2303.
102. Lieschke GJ, Burgess AW,. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (2). N Engl J Med 1992; 327: 99-106.
103. Dale DC, Liles WC, Summer WR, Nelson S,. Review: Granulocyte colony-stimulating factor-role and relationships in infectious diseases. J Infect Dis 1995; 172: 1061-1075.
104. Root RK, Dale DC,. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor: Comparisons and potential for use in the treatment of infections in nonneutropenic patients. J Infect Dis 1999; 179 (Suppl 2): S342-S352.
105. Rowe JM, Andersen JW, Mazza JJ, et al. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: A study of the Eastern Cooperative Oncology Group (E1490). Blood 1995; 86: 457-462.
106. Gaviria JM, van Burik JA, Dale DC, Root RK, Liles WC,. Comparison of interferon-gamma, granulocyte colony-stimulating factor, and granulocyte-macrophage colony-stimulating factor for priming leukocyte-mediated hyphal damage of opportunistic fungal pathogens. J Infect Dis 1999; 179: 1038-1041.
107. Roilides E, Blake C, Holmes A, Pizzo PA, Walsh TJ,. Granulocyte- macrophage colony-stimulating factor and interferon-gamma prevent dexamethasone-induced immunosuppression of antifungal monocyte activity against Aspergillus fumigatus hyphae. J Med Vet Mycol 1996; 34: 63-69.
108. Nagai H, Guo J, Choi H, Kurup V,. Interferon-gamma and tumor necrosis factor-alpha protect mice from invasive aspergillosis. J Infect Dis 1995; 172: 1554-1560.
109. Rex JH, Bennett JE, Gallin JI, Malech HL, DeCarlo ES, Melnick DA,. In vivo interferon-gamma therapy augments the in vitro ability of chronic granulomatous disease neutrophils to damage Aspergillus hyphae. J Infect Dis 1991; 163: 849-852.
110. Summers SA, Dorling A, Boyle JJ, Shaunak S,. Cure of disseminated cryptococcal infection in a renal allograft recipient after addition of gamma-interferon to anti-fungal therapy. Am J Transplant 2005; 5: 2067-2069.
111. Mamishi S, Zomorodian K, Saadat F, Gerami-Shoar M, Tarazooie B, Siadati SA,. A case of invasive aspergillosis in CGD patient successfully treated with Amphotericin B and INF-gamma. Ann Clin Microbiol Antimicrob 2005; 4: 4.
112. Saulsbury FT., Successful treatment of Aspergillus brain abscess with itraconazole and interferon-gamma in a patient with chronic granulomatous disease. Clin Infect Dis 2001; 32: E137-E139.
113. Pasic S, Abinun M, Pistignjat B, et al. Aspergillus osteomyelitis in chronic granulomatous disease: Treatment with recombinant gamma-interferon and itraconazole. Pediatr Infect Dis J 1996; 15: 833-834.
114. Cruciani M, Mengoli C, Malena M, Bosco O, Serpelloni G, Grossi P,. Antifungal prophylaxis in liver transplant patients: A systematic review and meta-analysis. Liver Transpl 2006; 12: 850-858.
115. Hellinger WC, Bonatti H, Yao JD, et al. Risk stratification and targeted antifungal prophylaxis for prevention of aspergillosis and other invasive mold infections after liver transplantation. Liver Transpl 2005; 11: 656-662.
116. Reed A, Herndon JB, Ersoz N, et al. Effect of prophylaxis on fungal infection and costs for high-risk liver transplant recipients. Liver Transpl 2007; 13: 1743-1750.
117. Singhal S, Ellis RW, Jones SG, et al. Targeted prophylaxis with amphotericin B lipid complex in liver transplantation. Liver Transpl 2000; 6: 588-595.
118. Fortun J, Martin-Davila P, Montejo M, et al. Prophylaxis with caspofungin for invasive fungal infections in high-risk liver transplant recipients. Transplantation 2009; 87: 424-435.
119. Naqvi R, Naqvi A, Akhtar S, et al. Use of isoniazid chemoprophylaxis in renal transplant recipients. Nephrol Dial Transplant 2009.
120. Borro JM, Sole A, de la TM, et al. Efficiency and safety of inhaled amphotericin B lipid complex (abelcet. in the prophylaxis of invasive fungal infections following lung transplantation. Transplant Proc 2008; 40: 3090-3093.
121. Drew RH, Dodds AE, Benjamin DK, Jr., Duane DR, Palmer SM, Perfect JR,. Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients. Transplantation 2004; 77: 232-237.
122. Minari A, Husni R, Avery RK, et al. The incidence of invasive aspergillosis among solid organ transplant recipients and implications for prophylaxis in lung transplants. Transpl Infect Dis 2002; 4: 195-200.
123. Monforte V, Roman A, Gavalda J, et al. Nebulized amphotericin B prophylaxis for Aspergillus infection in lung transplantation: Study of risk factors. J Heart Lung Transplant 2001; 20: 1274-1281.
124. Monforte V, Roman A, Gavalda J, et al. Nebulized liposomal amphotericin B (n-LAB) prophylaxis for Aspergillus infection in lung transplantation (LT): Pharmacokinetics, safety and efficacy. J Heart Lung Transplant 2009; 24: S108-S109.
125. Calvo V, Borro JM, Morales P, et al. Antifungal prophylaxis during the early postoperative period of lung transplantation. Valencia Lung Transplant Group. Chest 1999; 115: 1301-1304.
126. Reichenspurner H, Gamberg P, Nitschke M, et al. Significant reduction in the number of fungal infections after lung-, heart-lung, and heart transplantation using aerosolized amphotericin B prophylaxis. Transplant Proc 1997; 29: 627-628.
127. Hamacher J, Spiliopoulos A, Kurt AM, Nicod LP,. Pre-emptive therapy with azoles in lung transplant patients. Geneva Lung Transplantation Group. Eur Respir J 1999; 13: 180-186.
128. Palmer SM, Drew RH, Whitehouse JD, et al. Safety of aerosolized amphotericin B lipid complex in lung transplant recipients. Transplantation 2001; 72: 545-548.
129. Monforte V, Roman A, Gavalda J, et al. Nebulized amphotericin B concentration and distribution in the respiratory tract of lung-transplanted patients. Transplantation 2003; 75: 1571-1574.
130. Wahidi MM, Willner DA, Snyder LD, Hardison JL, Chia JY, Palmer SM,. Diagnosis and outcome of early pleural space infection following lung transplantation. Chest 2009; 135: 484-491.
131. Luong ML, Hosseini-Moghaddam SM, Singer LG, et al. Risk factors for voriconazole hepatotoxicity at 12 weeks in lung transplant recipients. Am J Transplant 2012; 12: 1929-1935.
132. Cadena J, Levine DJ, Angel LF, et al. Antifungal prophylaxis with voriconazole or itraconazole in lung transplant recipients: Hepatotoxicity and effectiveness. Am J Transplant 2009; 9: 2085-2091.
133. Vadnerkar A, Nguyen MH, Mitsani D, et al. Voriconazole exposure and geographic location are independent risk factors for squamous cell carcinoma of the skin among lung transplant recipients. J Heart Lung Transplant 2010; 29: 1240-1244.
134. Singer JP, Boker A, Metchnikoff C, et al. High cumulative dose exposure to voriconazole is associated with cutaneous squamous cell carcinoma in lung transplant recipients. J Heart Lung Transplant 2012; 31: 694-699.
135. Zwald FO, Spratt M, Lemos BD, et al. Duration of voriconazole exposure: An independent risk factor for skin cancer after lung transplantation. Dermatol Surg 2012; 10-4725.
136. Wang TF, Wang T, Altman R, et al. Periostitis secondary to prolonged voriconazole therapy in lung transplant recipients. Am J Transplant 2009; 9: 2845-2850.
137. Wermers RA, Cooper K, Razonable RR, et al. Fluoride excess and periostitis in transplant patients receiving long-term voriconazole therapy. Clin Infect Dis 2011; 52: 604-611.
138. Michael C, Bierbach U, Frenzel K, et al. Voriconazole pharmacokinetics and safety in immunocompromised children compared to adult patients. Antimicrob Agents Chemother 2010; 54: 3225-3232.
139. Soler-Palacin P, Frick MA, Martin-Nalda A, et al. Voriconazole drug monitoring in the management of invasive fungal infection in immunocompromised children: A prospective study. J Antimicrob Chemother 2012; 67: 700-706.